Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GLL022
MIFTS: 66

Guillain-Barre Syndrome

Categories: Genetic diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Guillain-Barre Syndrome

About this section

MalaCards integrated aliases for Guillain-Barre Syndrome:

Name: Guillain-Barre Syndrome 12 54 26 38 56 44 45 15 17 74
Guillain-Barré Syndrome 77 54 26 55 3
Fisher Syndrome 26 55 38
Acute Inflammatory Demyelinating Polyneuropathy 54 74
Acute Inflammatory Polyneuropathy 54 26
Gbs 54 26
Acute Inflammatory Demyelinating Polyradiculoneuropathy 54
Acute Autoimmune Peripheral Neuropathy 54
Landry-Guillain-Barre-Strohl Syndrome 54
Acute Immune-Mediated Polyneuropathy 54
Acute Postinfectious Polyneuropathy 12
Guillain-Barré-Strohl Syndrome 54
Landry-Guillain-Barre Syndrome 26
Acute Inflammatory Neuropathy 54
Acute Infectious Polyneuritis 26
Acute Infective Polyneuritis 12
Post-Infectious Polyneuritis 12
Landry's Ascending Paralysis 54
Postinfectious Polyneuritis 12
Post-Infective Polyneuritis 54
Miller Fisher Syndrome 74
Infectious Neuronitis 12

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases Infectious diseases
Anatomical: Immune diseases Neuronal diseases Respiratory diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:12842
MeSH 45 D020275
NCIt 51 C116345
SNOMED-CT 69 40956001
ICD10 34 G61.0
Sources

Summaries for Guillain-Barre Syndrome

About this section
MedlinePlus : 44 Guillain-Barre syndrome is a rare disorder that causes your immune system to attack your peripheral nervous system (PNS). The PNS nerves connect your brain and spinal cord with the rest of your body. Damage to these nerves makes it hard for them to transmit signals. As a result, your muscles have trouble responding to your brain. No one knows what causes the syndrome. Sometimes it is triggered by an infection, surgery, or a vaccination. The first symptom is usually weakness or a tingling feeling in your legs. The feeling can spread to your upper body. In severe cases, you become almost paralyzed. This is life-threatening. You might need a respirator to breathe. Symptoms usually worsen over a period of weeks and then stabilize. Guillain-Barre can be hard to diagnose. Possible tests include nerve tests and a spinal tap. Most people recover. Recovery can take a few weeks to a few years. Treatment can help symptoms, and may include medicines or a procedure called plasma exchange. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Guillain-Barre Syndrome, also known as guillain-barré syndrome, is related to miller fisher syndrome and peripheral nervous system disease, and has symptoms including seizures, tremor and back pain. An important gene associated with Guillain-Barre Syndrome is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are NF-kappaB Signaling and Allograft rejection. The drugs Immunologic Factors and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and spinal cord, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 An autoimmune disease of peripheral nervous system that causes body's immune system to attack part of the peripheral nervous system.

Genetics Home Reference : 26 Guillain-Barré syndrome is an autoimmune disorder that affects the nerves. Autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs. In Guillain-Barré syndrome, the immune response damages peripheral nerves, which are the nerves that connect the central nervous system (the brain and spinal cord) to the limbs and organs. Specifically, the immune response affects a particular part of peripheral nerves called axons, which are the extensions of nerve cells (neurons) that transmit nerve impulses. Guillain-Barré syndrome can affect the neurons that control muscle movement (motor neurons); the neurons that transmit sensory signals such as pain, temperature, and touch (sensory neurons); or both. As a result, affected individuals can experience muscle weakness or lose the ability to feel certain sensations.

NIH Rare Diseases : 54 Guillain-Barré syndrome (GBS) is a rare syndrome in which the body�??s immune system attacks part of the peripheral nervous system. The peripheral nervous system carries signals from the brain to the muscles. Symptoms of GBS include muscle weakness, numbness, and tingling sensations, which can increase in intensity until the muscles cannot be used at all (paralysis). The exact cause of Guillain-Barré syndrome is unknown. In most cases, GBS occurs a few days or weeks after symptoms of a viral infection. In rare cases, GBS may run in families. A diagnosis of GBS is suspected when a person has symptoms suggestive of the syndrome. A variety of tests, including a spinal tap, may be completed to confirm the diagnosis. Treatment options may include plasma exchange (plasmapheresis) and immunoglobulin therapy. 

CDC : 3 Guillain-Barré syndrome (GBS) is a rare disorder where the body’s immune system damages nerve cells, causing muscle weakness and sometimes paralysis. While its cause is not fully understood, the syndrome often follows infection with a virus or bacteria. In the United States, an estimated 3,000 to 6,000 people develop GBS each year. Most people recover fully from GBS, but some have permanent nerve damage.

NINDS : 55 Miller Fisher syndrome is a rare, acquired nerve disease that is considered to be a variant of Guillain-Barré syndrome. It is characterized by abnormal muscle coordination, paralysis of the eye muscles, and absence of the tendon reflexes. Like Guillain-Barré syndrome, symptoms may be preceded by a viral illness. Additional symptoms include generalized muscle weakness and respiratory failure. The majority of individuals with Miller Fisher syndrome have a unique antibody that characterizes the disorder.

Wikipedia : 77 Guillain–Barré syndrome (GBS) is a rapid-onset muscle weakness caused by the immune system damaging the... more...

Sources

Related Diseases for Guillain-Barre Syndrome

About this section

Diseases in the Guillain-Barre Syndrome family:

Guillain-Barre Syndrome, Familial

Diseases related to Guillain-Barre Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 564)
# Related Disease Score Top Affiliating Genes
1 miller fisher syndrome 33.9 HMGA2 TNF
2 peripheral nervous system disease 32.2 ALB MBP MPZ PMP22 TNF
3 polyneuropathy 30.9 MBP MPZ PMP22
4 pustulosis of palm and sole 30.9 TNF TNFRSF1B
5 demyelinating disease 30.8 MBP TNF TNFRSF1A
6 demyelinating polyneuropathy 30.7 ALB HP PMP22
7 optic neuritis 30.4 MBP MPZ TNF
8 juvenile rheumatoid arthritis 30.3 HLA-DQA1 TNF TNFRSF1B
9 membranous nephropathy 30.2 ALB HLA-DQA1 TNF
10 toxoplasmosis 30.2 HLA-DQA1 HLA-DQB1 TNF
11 neuritis 30.2 MBP MPZ PMP2 PMP22 TNF
12 liver disease 30.2 ALB FAS TNF TNFRSF1A
13 autoimmune disease 30.2 FAS HLA-DQB1 MBP TNF
14 multiple sclerosis 30.2 HLA-DQB1 MBP MPZ TNF TNFRSF1A
15 leishmaniasis 30.2 HLA-DQA1 HLA-DQB1 TNF
16 chronic inflammatory demyelinating polyradiculoneuropathy 30.1 ALB MPZ PMP22 TNFRSF1A
17 pelizaeus-merzbacher disease 30.1 MBP MPZ PMP22
18 rheumatoid arthritis 30.1 HLA-DQA1 HLA-DQB1 TNF TNFRSF1A TNFRSF1B
19 graft-versus-host disease 30.1 FAS HLA-DQB1 TNF
20 psoriatic arthritis 30.0 TNF TNFRSF1A TNFRSF1B
21 acute disseminated encephalomyelitis 30.0 HCRT HLA-DQA1 HLA-DQB1 MBP MPZ
22 viral hepatitis 30.0 ALB FAS HLA-DQA1 TNF
23 vogt-koyanagi-harada disease 29.9 FAS HLA-DQA1 HLA-DQB1
24 polyradiculoneuropathy 29.9 ALB MBP MPZ PMP2 PMP22
25 type ii mixed cryoglobulinemia 29.8 FAS HLA-DQB1
26 charcot-marie-tooth disease 29.8 MBP MPZ PMP2 PMP22
27 systemic lupus erythematosus 29.4 ALB FAS HLA-DQA1 HLA-DQB1 TNF TNFRSF1A
28 diabetes mellitus 29.4 ALB FAS HLA-DQA1 HLA-DQB1 TNF
29 guillain-barre syndrome, familial 13.0
30 kozlowski warren fisher syndrome 12.2
31 chronic inflammatory demyelinating polyneuropathy 11.8
32 dysautonomia 11.7
33 zika virus infection 11.7
34 acute flaccid myelitis 11.5
35 chronic polyradiculoneuritis 11.4
36 combined immunodeficiency with skin granulomas 11.4
37 lewis-sumner syndrome 11.4
38 thyrotoxic periodic paralysis 11.4
39 neuropathy, hereditary sensory and autonomic, type iii 11.4
40 facial diplegia with paresthesias 11.0
41 bickerstaff brainstem encephalitis 11.0
42 acute motor and sensory axonal neuropathy 10.9
43 herpes simplex 10.6
44 influenza 10.5
45 acute pandysautonomia 10.5
46 acute sensory ataxic neuropathy 10.5
47 paraparetic variant of guillain-barré syndrome 10.5
48 acute pure sensory neuropathy 10.5
49 pharyngeal-cervical-brachial variant of guillain-barré syndrome 10.5
50 acute motor axonal neuropathy 10.5

Graphical network of the top 20 diseases related to Guillain-Barre Syndrome:



Diseases related to Guillain-Barre Syndrome
Sources

Symptoms & Phenotypes for Guillain-Barre Syndrome

About this section

UMLS symptoms related to Guillain-Barre Syndrome:


seizures, tremor, back pain, ophthalmoplegia, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, cerebellar ataxia, neuralgia

MGI Mouse Phenotypes related to Guillain-Barre Syndrome:

47 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.28 FAS HCRT HLA-DQB1 MBP MPZ PMP2
2 homeostasis/metabolism MP:0005376 10.28 ALB DAAM2 FAS HCRT HLA-DQB1 HP
3 cellular MP:0005384 10.25 ALB FAS HLA-DQB1 HP MBP MPZ
4 cardiovascular system MP:0005385 10.18 DAAM2 FAS HCRT HLA-DQB1 HP TH
5 growth/size/body region MP:0005378 10.18 DAAM2 FAS HCRT HLA-DQB1 MBP PMP22
6 hematopoietic system MP:0005397 10.11 FAS HLA-DQA1 HLA-DQB1 HP MBP MPZ
7 mortality/aging MP:0010768 10.11 ALB FAS HLA-DQB1 HP MBP MPZ
8 endocrine/exocrine gland MP:0005379 10.1 ALB FAS HLA-DQA1 HLA-DQB1 TH TNF
9 liver/biliary system MP:0005370 10.01 ALB FAS HLA-DQB1 HP TH TNF
10 muscle MP:0005369 9.92 ALB DAAM2 HCRT HLA-DQB1 PMP22 TNF
11 nervous system MP:0003631 9.9 FAS HCRT HLA-DQB1 MBP MPZ PMP2
12 neoplasm MP:0002006 9.8 ALB FAS HP TH TNF TNFRSF1A
13 respiratory system MP:0005388 9.5 FAS HCRT HLA-DQB1 TH TNF TNFRSF1A
14 vision/eye MP:0005391 9.17 FAS MBP PMP22 TH TNF TNFRSF1A
Sources

Drugs & Therapeutics for Guillain-Barre Syndrome

About this section

Drugs for Guillain-Barre Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunologic Factors Phase 4,Phase 3,Phase 2,Not Applicable
2 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
3
Pembrolizumab Approved Phase 3 1374853-91-4
4 Immunoglobulins Phase 3,Phase 2,Not Applicable
5 Antibodies Phase 3,Phase 2,Not Applicable
6 Antineoplastic Agents, Immunological Phase 3
7
4-Aminopyridine Approved Phase 2 504-24-5 1727
8
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
9
Lactitol Investigational Phase 2 585-88-6, 585-86-4 493591
10 Complement System Proteins Phase 2
11 Pharmaceutical Solutions Phase 2,Not Applicable
12 Immunoglobulins, Intravenous Phase 2,Not Applicable
13 Rho(D) Immune Globulin Phase 2,Not Applicable
14 gamma-Globulins Phase 2,Not Applicable
15 Potassium Channel Blockers Phase 2
16 MF59 oil emulsion Phase 2
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
18 Hormone Antagonists Phase 2
19 Antineoplastic Agents, Hormonal Phase 2
20 Anti-Inflammatory Agents Phase 2
21 glucocorticoids Phase 2
22 Hormones Phase 2
23 Hemagglutinins Phase 2
24 Immunoglobulin G Phase 2
25
Sodium Citrate Approved, Investigational Not Applicable 68-04-2
26
Infliximab Approved 170277-31-3
27
nivolumab Approved 946414-94-4
28
Thiamine Approved, Investigational, Nutraceutical, Vet_approved 70-16-6, 59-43-8 1130
29
Calcium Approved, Nutraceutical Not Applicable 7440-70-2 271
30
Citric Acid Approved, Nutraceutical, Vet_approved Not Applicable 77-92-9 311
31 Vitamin B Complex
32 Vitamins
33 Thiamin
34 Anticoagulants Not Applicable
35 Calcium, Dietary Not Applicable
36 Chelating Agents Not Applicable
37 Citrate Not Applicable
38 Gastrointestinal Agents
39 Dermatologic Agents
40 Antirheumatic Agents
41 Hemostatics Not Applicable
42 Coagulants Not Applicable
43 Autoantibodies

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults Completed NCT01427309 Phase 4
2 Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome Completed NCT02342184 Phase 3 GB-0998
3 Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome Completed NCT02221271 Phase 3 NPB-01
4 Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801 Completed NCT01604746 Phase 3
5 Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination Completed NCT01934140 Phase 3
6 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
7 A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered). Completed NCT03189745 Phase 3
8 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) Recruiting NCT03486873 Phase 3 Standard of Care (SOC)
9 Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older Terminated NCT00976027 Phase 3
10 Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study Unknown status NCT02029378 Phase 2 Eculizumab
11 Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) Patients Completed NCT02780570 Phase 2
12 Early Mechanical Ventilation for Guillain Barré Syndrome Completed NCT00167622 Phase 2
13 Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine Completed NCT00056810 Phase 2 4-aminopyridine (4-AP)
14 JET-GBS - Japanese Eculizumab Trial for GBS Completed NCT02493725 Phase 2 Eculizumab;Placebo
15 Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure Completed NCT03174964 Phase 2 IVIg
16 Seasonal Flu Vaccine in Adult Transplant Recipients Completed NCT01258023 Phase 2
17 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2 Prednisone;Prednisone
18 Sanofi H1N1 + TIV - Adults and Elderly Completed NCT00943878 Phase 2 Placebo
19 Novartis H1N1 Vaccine in Pregnant Women Completed NCT00992719 Phase 2
20 2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women Completed NCT01173211 Phase 2
21 Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations Completed NCT00963157 Phase 2 AS03
22 H1N1 Vaccine at Two Dose Levels in HIV Positive Adults Completed NCT00992433 Phase 2
23 Sanofi Pasteur, TIV + H1N1, Pediatric Population Completed NCT00943202 Phase 2
24 H1N1 Vaccine in Pregnant Women Completed NCT00963430 Phase 2
25 A Study of Imlifidase in Patients With Guillain-Barré Syndrome Not yet recruiting NCT03943589 Phase 2 Imlifidase
26 Study of GLS-5700 in Dengue Virus Seropositive Adults Completed NCT02887482 Phase 1
27 Study of GLS-5700 in Healthy Volunteers Completed NCT02809443 Phase 1
28 A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS) Suspended NCT03773328 Phase 1
29 International Guillain-Barré Syndrome Outcome Study Unknown status NCT01582763
30 sCD163 as a Potential Biomarker in Guillain- Barré Syndrome Unknown status NCT02582853
31 The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin Innervation Unknown status NCT00173199
32 Change of Nerve Conduction Properties in IVIg Dependent Neuropathies Unknown status NCT01655394
33 Detection of Peripheral Blood Biomarkers in Intermediate Phase Spinal Cord Injury: Correlation With Neurological and Functional Outcomes, and Comparison to Other Central and Peripheral Neurological Conditions. Unknown status NCT01516385
34 Thiamin (Vitamin B1) Levels in Eating Disorder Adolescent Patients Unknown status NCT02164487
35 Perception and Multisensory Integration in Neurological Patients Using fMRI Unknown status NCT01469858 Not Applicable
36 Intravenous Immunoglobulin (IVIG) Versus Plasma Exchange (PE) for Ventilated Children With Guillain Barre Syndrome (GBS) Completed NCT01306578 Not Applicable IVIG
37 Safety Study of GBS Following Menactra Meningococcal Vaccination Completed NCT00575653
38 Effects of Robotic-assisted Gait Training In Non-Ambulatory Patients After Guillain-Barré Syndrome Completed NCT02883270 Not Applicable
39 Prospective Study on Swallowing/Breathing Interactions in Severe Guillain Barre Syndrome. Completed NCT01024088
40 Brain Computer Interface for Communication in ICU: a Feasibility Study Completed NCT01005524
41 Regional Citrate Anticoagulation in Plasma Exchange Treatment Completed NCT01370200 Not Applicable
42 Cervarix Long-term Safety Surveillance Completed NCT01498627
43 Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom Completed NCT01953822
44 Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age Completed NCT01985997
45 Surveillance for Adverse Events Following Pandemic H1N1 Immunization Completed NCT01289418
46 Surveillance for Adverse Events Following Influenza Immunization Completed NCT01318876
47 Database Surveillance Safety Study of PENTACEL® Vaccine Completed NCT00804284
48 Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines Completed NCT02893878
49 Recovery of Visual Acuity in People With Vestibular Deficits Completed NCT00411216 Not Applicable
50 Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035) Completed NCT00705614

Search NIH Clinical Center for Guillain-Barre Syndrome

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: guillain-barre syndrome

Sources

Genetic Tests for Guillain-Barre Syndrome

About this section
Sources

Anatomical Context for Guillain-Barre Syndrome

About this section

MalaCards organs/tissues related to Guillain-Barre Syndrome:

42
Brain, Testes, Spinal Cord, T Cells, Heart, Eye, Skin
Sources

Publications for Guillain-Barre Syndrome

About this section

Articles related to Guillain-Barre Syndrome:

(show top 50) (show all 3022)
# Title Authors Year
1
An overlapping case of Bickerstaff brainstem encephalitis and acute motor axonal neuropathy variant of Guillain-Barré syndrome associated with systemic lupus erythematosus. ( 30444497 )
2019
2
A rare mimic of acute stroke: rapidly progressing Miller-Fisher Syndrome to acute motor and sensory axonal neuropathy variant of Guillain-Barre Syndrome. ( 30936342 )
2019
3
Guillain Barré syndrome heralding the diagnosis of angioimmunoblastic T-cell lymphoma. ( 30648445 )
2019
4
Zika Virus-Associated Aseptic Meningitis and Guillain-Barre Syndrome in a Traveler Returning from Latin America: a Case Report and Mini-Review. ( 30767073 )
2019
5
Bell's palsy and Guillain-Barré syndrome may be two ends of the same spectrum. ( 30908681 )
2019
6
Dry Beriberi Due to Thiamine Deficiency Associated with Peripheral Neuropathy and Wernicke's Encephalopathy Mimicking Guillain-Barré syndrome: A Case Report and Review of the Literature. ( 30862772 )
2019
7
Bickerstaff Brainstem Encephalitis and overlapping Guillain-Barré syndrome in children: Report of two cases and review of the literature. ( 30502045 )
2019
8
Rare variant of Guillain-Barré syndrome after chikungunya viral fever. ( 31015248 )
2019
9
Co-existent ulcerative colitis and Guillain-Barré syndrome: a case report and literature review. ( 30778832 )
2019
10
Dysautonomia and hyponatraemia as harbingers of Guillain-Barre syndrome. ( 30992282 )
2019
11
Severe bornavirus-encephalitis presenting as Guillain-Barré-syndrome. ( 30953131 )
2019
12
Concurrent Guillain-Barré syndrome, transverse myelitis and encephalitis post-Zika and multiple arboviral immunity. ( 30401491 )
2019
13
A case report of Guillain Barré syndrome revealing underlying infective endocarditis due to Cardiobacterium hominis. ( 30985649 )
2019
14
Froin's Syndrome Mimicking Guillain-Barre Syndrome in a Patient with Spinal Epidural Abscess. ( 30937072 )
2019
15
Guillain-Barré syndrome subtypes: A clinical electrophysiological study of 100 patients. ( 30442448 )
2019
16
Spontaneous spinal epidural hematoma mimicking Guillain-Barre Syndrome. ( 30471873 )
2019
17
Outcomes of patients with Guillain Barre Syndrome - Experience from a tertiary care hospital of a developing Asian country and review of regional literature. ( 30477890 )
2019
18
Guillain-Barré syndrome in Denmark: a population-based study on epidemiology, diagnosis and clinical severity. ( 30536111 )
2019
19
Dysglycemia and Neurologic Outcome in Mechanically Ventilated Patients With Guillain-Barré Syndrome. ( 30585828 )
2019
20
Guillain-Barré Syndrome Related to Nivolumab: Case Report of a Patient With Urothelial Cancer and Review of the Literature. ( 30612920 )
2019
21
Incidence study of Guillain-Barré syndrome in the province of Ferrara, Northern Italy, between 2003 and 2017. A 40-year follow-up. ( 30617450 )
2019
22
Fulminant Guillain-Barré syndrome in a patient with systemic lupus erythematosus. ( 30642853 )
2019
23
IVIg-induced plasmablasts in patients with Guillain-Barré syndrome. ( 30656191 )
2019
24
Do All Children with Guillain Barré Syndrome Need Immunotherapy? ( 30659495 )
2019
25
Ayurveda management of Guillain-Barre syndrome: A case report. ( 30661945 )
2019
26
Intravenous Immunoglobulin for Severe Protracted Pediatric Guillain-Barre Syndrome: Is Single Dose Adequate? ( 30692777 )
2019
27
A Novel Treatment Strategy for Severe Guillain-Barré Syndrome: Zipper Method. ( 30696330 )
2019
28
Integrative metabolomics reveals unique metabolic traits in Guillain-Barré Syndrome and its variants. ( 30705347 )
2019
29
Dynamic thiol-disulphide homeostasis in patients with Guillain-Barre Syndrome. ( 30730791 )
2019
30
Differentiation Between Guillain-Barré Syndrome and Acute-Onset Chronic Inflammatory Demyelinating Polyradiculoneuritis-a Prospective Follow-up Study Using Ultrasound and Neurophysiological Measurements. ( 30756363 )
2019
31
A Unique Case of a Pediatric Patient With Blastic Plasmacytoid Dendritic Cell Neoplasm, Guillain Barre Syndrome, and Hemophagocytic Lymphohistiocytosis. ( 30933025 )
2019
32
Guillain-Barre Syndrome and Zika infection: Identifying leading producers, countries relative specialization, and collaboration. ( 30759205 )
2019
33
Assessing seasonal dynamics of Guillain-Barré syndrome with search engine query data. ( 30762168 )
2019
34
Efficient design and analysis of randomized controlled trials in rare neurological diseases: An example in Guillain-Barré syndrome. ( 30785890 )
2019
35
Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome. ( 30788172 )
2019
36
Outbreak of Guillain-Barre syndrome in Peru. ( 30788441 )
2019
37
Elevated resistin levels may regulate high mobility group box 1 expression in Guillain-Barré syndrome. ( 30826699 )
2019
38
Paralytic rabies: A Guillain-Barre Syndrome mimic. ( 30830154 )
2019
39
Risk factors for respiratory failure in Guillain-Barré syndrome in Bangladesh: a prospective study. ( 30847364 )
2019
40
Guillain-Barré syndrome as a complication of hypertensive basal ganglia haemorrhage. ( 30852075 )
2019
41
Antibodies to dengue, Zika, Campylobacter jejuni and gangliosides in Guillain-Barre syndrome. ( 30860160 )
2019
42
Virus-triggered spinal cord demyelination is followed by a peripheral neuropathy resembling features of Guillain-Barré Syndrome. ( 30872675 )
2019
43
Prevalence and outcomes of Guillain-Barré syndrome among pediatrics in Saudi Arabia: a 10-year retrospective study. ( 30880987 )
2019
44
Guillain-Barré syndrome in a patient of acute Hepatitis E virus infection associated with genotype 1: Case report and literature review. ( 30881857 )
2019
45
Guillain-Barré syndrome associated with Zika virus infection in Brazil: a cost-of-illness study. ( 30892628 )
2019
46
Guillain-Barre syndrome: a rare complication of leptospirosis and scrub typhus co-infection. ( 30895887 )
2019
47
Guillain-Barré Syndrome and Its Variants: Clinical Course and Prognostic Factors. ( 30911241 )
2019
48
Guillain-Barré syndrome with unilateral peripheral facial and bulbar palsy in a child: A case report. ( 30915222 )
2019
49
A unicenter, prospective study of Guillain-Barré syndrome in Spain. ( 30929269 )
2019
50
Clinical Characteristics of Intravenous Injection of Monosialotetrahexosyl Ganglioside Sodium-Related Guillain-Barre Syndrome. ( 30930839 )
2019
Sources

Variations for Guillain-Barre Syndrome

About this section
Sources

Expression for Guillain-Barre Syndrome

About this section
Search GEO for disease gene expression data for Guillain-Barre Syndrome.
Sources

Pathways for Guillain-Barre Syndrome

About this section

Pathways related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
NF-kappaB Signaling 4
12.41 FAS TNF TNFRSF1A TNFRSF1B
2
Allograft rejection 38 1
Show member pathways
 12.37 FAS HLA-DQA1 HLA-DQB1 TNF TNFRSF1A TNFRSF1B
3
DREAM Repression and Dynorphin Expression 65
Show member pathways
 12.34 FAS TNF TNFRSF1A TNFRSF1B
4
Immune response NFAT in immune response 23
Show member pathways
 12.28 HLA-DQA1 HLA-DQB1 TNF TNFRSF1A TNFRSF1B
5
Human T-cell leukemia virus 1 infection 38
12.2 HLA-DQA1 HLA-DQB1 TNF TNFRSF1A
6
TNF signaling (REACTOME) 1
Show member pathways
 12.16 FAS TNF TNFRSF1A TNFRSF1B
7
Toxoplasmosis 38
Show member pathways
 12.07 HLA-DQA1 HLA-DQB1 TNF TNFRSF1A
8
Apoptosis and Autophagy 4
12.05 FAS TNF TNFRSF1A TNFRSF1B
9
Tuberculosis 38
11.99 HLA-DQA1 HLA-DQB1 TNF TNFRSF1A
10
Amyotrophic lateral sclerosis (ALS) 1 38
Show member pathways
 11.84 TNF TNFRSF1A TNFRSF1B
11
Neural Crest Differentiation 1
11.78 MBP MPZ PMP22
12
Hematopoietic cell lineage 38
11.75 HLA-DQA1 HLA-DQB1 TNF
13
Rheumatoid arthritis 38
11.7 HLA-DQA1 HLA-DQB1 TNF
14
Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway 23
Show member pathways
 11.59 TNF TNFRSF1A TNFRSF1B
15
Adipocytokine signaling pathway 38
11.55 TNF TNFRSF1A TNFRSF1B
16
Transcription_NF-kB signaling pathway 23
11.42 TNF TNFRSF1A TNFRSF1B
17
Photodynamic therapy-induced AP-1 survival signaling. 1
11.34 FAS TNF TNFRSF1A
18
Cellular Transformation by HTLV1 65
Show member pathways
 11.28 TNF TNFRSF1A TNFRSF1B
19
Interleukin-10 signaling 67
11.23 TNF TNFRSF1A TNFRSF1B
20
Signal transduction_JNK pathway 23
11.08 FAS TNF TNFRSF1A
21
TNF signaling pathway 38
10.97 FAS TNF TNFRSF1A TNFRSF1B
22
14-3-3 and Regulation of BAD Activity 65
10.64 TNF TNFRSF1A TNFRSF1B
Sources

GO Terms for Guillain-Barre Syndrome

About this section

Cellular components related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.56 FAS TNF TNFRSF1A TNFRSF1B
2 MHC class II protein complex GO:0042613 9.32 HLA-DQA1 HLA-DQB1
3 compact myelin GO:0043218 9.16 MBP PMP22
4 myelin sheath GO:0043209 9.13 MBP MPZ PMP2
5 tumor necrosis factor receptor superfamily complex GO:0002947 8.62 TNFRSF1A TNFRSF1B

Biological processes related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.86 HCRT MBP MPZ PMP22
2 tumor necrosis factor-mediated signaling pathway GO:0033209 9.7 TNF TNFRSF1A TNFRSF1B
3 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.61 TNF TNFRSF1A TNFRSF1B
4 negative regulation of cardiac muscle hypertrophy GO:0010614 9.58 TNFRSF1A TNFRSF1B
5 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.58 TNF TNFRSF1B
6 myelination GO:0042552 9.58 MBP MPZ PMP22
7 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.57 HLA-DQA1 HLA-DQB1
8 positive regulation of ceramide biosynthetic process GO:2000304 9.55 TNF TNFRSF1A
9 response to salt stress GO:0009651 9.54 TH TNF
10 extrinsic apoptotic signaling pathway GO:0097191 9.54 FAS TNF TNFRSF1B
11 cellular response to nicotine GO:0071316 9.51 TH TNF
12 death-inducing signaling complex assembly GO:0071550 9.49 TNF TNFRSF1A
13 regulation of establishment of endothelial barrier GO:1903140 9.48 TNF TNFRSF1A
14 necroptotic signaling pathway GO:0097527 9.46 FAS TNF
15 aortic valve development GO:0003176 9.32 TNFRSF1A TNFRSF1B
16 negative regulation of extracellular matrix constituent secretion GO:0003332 9.26 TNFRSF1A TNFRSF1B
17 positive regulation of apoptotic process involved in morphogenesis GO:1902339 9.16 TNFRSF1A TNFRSF1B
18 immune response GO:0006955 9.1 FAS HLA-DQA1 HLA-DQB1 MBP TNF TNFRSF1B
19 pulmonary valve development GO:0003177 8.96 TNFRSF1A TNFRSF1B

Molecular functions related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 9.16 HLA-DQA1 HLA-DQB1
2 tumor necrosis factor-activated receptor activity GO:0005031 8.96 TNFRSF1A TNFRSF1B
3 tumor necrosis factor binding GO:0043120 8.62 TNFRSF1A TNFRSF1B
Sources

Sources for Guillain-Barre Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....